DAYANG BIOTECH(SZ:003017) Zheng Quan Zhi Xing·2025-08-29 17:46Core Viewpoint - Zhejiang Dayang Biological Technology Group Co., Ltd. announced a share reduction plan by its actual controllers and their concerted actors, which involves a total reduction of up to 839,123 shares, accounting for 1.00% of the company's total share capital [1][2][3]. Summary by Sections Shareholders' Information - The total number of shares held by the concerted actors is 2,140,518 shares, representing 2.56% of the company's total share capital [2]. - Individual holdings include: - Mr. Hao Bingyan: 1,123,595 shares (1.34%) - Mr. Qian Jianchun: 770,000 shares (0.92%) - Mr. Chen Shouliang: 199,123 shares (0.24%) - Ms. Zhao Yumei: 47,800 shares (0.06%) [1]. Reduction Plan Details - The share reduction will occur within three months following the announcement, excluding periods when reductions are prohibited by the Shenzhen Stock Exchange [1][3]. - The shares to be reduced are from those acquired before the company's IPO and through capital reserve conversion [2][3]. Compliance and Commitments - The shareholders have committed to not transferring or entrusting their shares for 36 months post-IPO, with specific conditions for any subsequent reductions [4]. - The shareholders have adhered to their commitments without any violations of regulations or agreements [4][5]. Impact on Company Governance - The planned share reduction will not lead to a change in control of the company and is not expected to significantly impact the company's governance structure or ongoing operations [5].